2023
Left ventricular hypertrophy and left atrial size are associated with ischemic strokes among non-vitamin K antagonist oral anticoagulant users
Das A, Gökçal E, Fouks A, Horn M, Regenhardt R, Viswanathan A, Singhal A, Schwamm L, Greenberg S, Gurol M. Left ventricular hypertrophy and left atrial size are associated with ischemic strokes among non-vitamin K antagonist oral anticoagulant users. Journal Of Neurology 2023, 270: 5578-5588. PMID: 37548681, PMCID: PMC11111216, DOI: 10.1007/s00415-023-11916-7.Peer-Reviewed Original ResearchPrior cerebrovascular eventsAtrial volume indexVentricular hypertrophyCerebrovascular eventsNOAC usersAtrial sizeIS recurrenceSevere white matter hyperintensitiesVolume indexCerebral small vessel diseaseOral anticoagulant usersChronic renal failureRisk of strokeCox regression analysisQuaternary care centerSmall vessel diseaseAge-matched controlsWhite matter hyperintensitiesMultivariable regression modelsAnticoagulant usersApixaban useDabigatran useResults112 patientsMultivariable adjustmentOral anticoagulants
2021
Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design
Li S, Campbell B, Schwamm L, Fisher M, Parsons M, Li H, Pan Y, Wang Y, . Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design. Stroke And Vascular Neurology 2021, 7: 71-76. PMID: 34446531, PMCID: PMC8899655, DOI: 10.1136/svn-2021-001074.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeExcellent functional outcomeFunctional outcomeReperfusion therapyRt-PAAcute ischemic cerebrovascular eventsIntravenous thrombolysis therapyMajor neurological improvementSecondary efficacy outcomesHealth Stroke ScaleIschemic cerebrovascular eventsSymptomatic intracranial hemorrhageFavorable functional outcomeIschemic stroke onsetPrimary study outcomeRankin Scale 0Non-inferiority studyTissue-type plasminogen activatorCerebrovascular eventsNeurological improvementStroke ScaleEfficacy outcomesIschemic strokeStroke onsetThrombolysis therapy
2006
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes–Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study
Smith E, Cannon C, Murphy S, Feske S, Schwamm L. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes–Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. American Heart Journal 2006, 151: 338-344. PMID: 16442896, DOI: 10.1016/j.ahj.2005.03.031.Peer-Reviewed Original ResearchConceptsTransient ischemic attackAcute coronary syndromeHistory of hypertensionPrior ischemic strokeIschemic strokeCerebrovascular eventsIntracranial hemorrhageRisk factorsCoronary syndromeHistory of TIAUnstable Coronary Syndromes-ThrombolysisHemorrhagic cerebrovascular eventsPlacebo-controlled trialCoronary artery diseaseLong-term patientsSignificant excess riskIschemic attackStroke outcomeArtery diseaseCoronary angiographyOverall incidenceCerebrovascular diseaseExcess riskHeart ratePatients